Spyre Therapeutics (SYRE) Revenue (2015 - 2023)

Spyre Therapeutics has reported Revenue for 7 years, with the latest figure at $688000.0 in Q2 2023.

• For the quarter ending Q2 2023, Revenue rose 10.08% year-over-year to $688000.0; the trailing twelve-month figure through Mar 2024 stood at $688000.0 (down 40.94% YoY), and the FY2023 full-year result was $886000.0, down 61.96% from the prior year.
• Revenue for Q2 2023 stood at $688000.0, up from $198000.0 in the prior quarter.
• The five-year high for Revenue was $12.0 million in Q2 2021, with the low at $168000.0 in Q4 2022.
• Historically, Revenue has averaged $3.4 million across 3 years, with a median of $688000.0 in 2023.
• Annual changes were most pronounced in 2022 — Revenue slumped 98.55% — and 2023, when it rose 10.08%.
• Spyre Therapeutics' Revenue stood at $3.6 million in 2021, then sank by 95.39% to $168000.0 in 2022, then surged by 309.52% to $688000.0 in 2023.
• The last three Revenue figures came in at $688000.0 (Q2 2023), $198000.0 (Q1 2023), and $168000.0 (Q4 2022), per Business Quant data.